- Home
- SPRY vs GAU Comparison
SPRY vs GAU Comparison
Compare SPRY & GAU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPRY | GAU |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 823.2M | 680.7M |
| IPO Year | 2020 | 2006 |
Fundamental Metrics
Financial Performance| Metric | SPRY | GAU |
|---|---|---|
| Price | $7.83 | $2.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $40.00 | $4.08 |
| AVG Volume (30 Days) | 1.5M | ★ 2.5M |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $84,278,000.00 | N/A |
| Revenue This Year | $87.40 | $82.77 |
| Revenue Next Year | $81.64 | $29.09 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.66 | $1.22 |
| 52 Week High | $18.63 | $3.62 |
Technical Indicators
Market Signals| Indicator | SPRY | GAU |
|---|---|---|
| Relative Strength Index (RSI) | 41.81 | 34.50 |
| Support Level | $7.20 | $2.14 |
| Resistance Level | $8.61 | $2.55 |
| Average True Range (ATR) | 0.39 | 0.10 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 19.23 | 4.55 |
Price Performance
Historical ComparisonAbout SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
About GAU Galiano Gold Inc.
Galiano Gold Inc is focused on building a sustainable business capable of long term value creation for its stakeholders through a combination of exploration, accretive acquisitions, and disciplined deployment of its financial resources. The company currently operates and manages: Nkran, Esaase, Abore and Miradani North, multiple satellite deposits and exploration projects located on the Asankrangwa Gold Belt in the Amansie West District of the Republic of Ghana (Ghana), West Africa.